Issued 2026-08-13 at $14.12 · now $14.07 (2026-08-13, −0.4% since)
Based on its own history, a month from the 2026-08-13 close, EVMN has typically landed between $8.74 and $21.04 — a range of −38.1% to +49.0% from the issuance price $14.12.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
170 overlapping 1 month windows · 2025-11-06 – 2026-07-15 · basis climatology · forecast (batch).
The cone is anchored at the 2026-08-13 issuance close ($14.12) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where EVMN has typically landed a month from the 2026-08-13 close of $14.12 — the range is history, not a prediction.
- now $14.07 (-0.4%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $13.36 (-5.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $11.43–$15.29
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.74–$21.04
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2026-06-26 | −55.3% | −55.3% | +0.0% |
| 2026-06-23 | −53.3% | −53.3% | +3.8% |
| 2026-06-25 | −52.5% | −53.1% | +4.4% |
| 3 best | |||
| 2026-01-16 | +71.0% | −0.8% | +87.9% |
| 2026-01-15 | +58.7% | −15.0% | +61.1% |
| 2026-01-23 | +58.2% | −11.7% | +67.3% |
170 overlapping windows · 2025-11-06 – 2026-08-13 · not cherry-picked
Pending catalysts
- October 2027 — Trial primary completion: Phase 2 primary completion: Study of EVO756 in Adults With Migraine (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.